Paired exome analysis of Barrett's esophagus and adenocarcinoma.

TitlePaired exome analysis of Barrett's esophagus and adenocarcinoma.
Publication TypeJournal Article
Year of Publication2015
AuthorsStachler MD, Taylor-Weiner A, Peng S, McKenna A, Agoston AT, Odze RD, Davison JM, Nason KS, Loda M, Leshchiner I, Stewart C, Stojanov P, Seepo S, Lawrence MS, Ferrer-Torres D, Lin J, Chang AC, Gabriel SB, Lander ES, Beer DG, Getz G, Carter SL, Bass AJ
JournalNat Genet
Volume47
Issue9
Pagination1047-55
Date Published2015 Sep
ISSN1546-1718
KeywordsAdenocarcinoma, Barrett Esophagus, Class I Phosphatidylinositol 3-Kinases, Cyclin-Dependent Kinase Inhibitor p16, DNA Mutational Analysis, Esophageal Neoplasms, Exome, Gene Amplification, Gene Frequency, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Phosphatidylinositol 3-Kinases, Point Mutation, Tumor Suppressor Protein p53
Abstract

Barrett's esophagus is thought to progress to esophageal adenocarcinoma (EAC) through a stepwise progression with loss of CDKN2A followed by TP53 inactivation and aneuploidy. Here we present whole-exome sequencing from 25 pairs of EAC and Barrett's esophagus and from 5 patients whose Barrett's esophagus and tumor were extensively sampled. Our analysis showed that oncogene amplification typically occurred as a late event and that TP53 mutations often occurred early in Barrett's esophagus progression, including in non-dysplastic epithelium. Reanalysis of additional EAC exome data showed that the majority (62.5%) of EACs emerged following genome doubling and that tumors with genomic doubling had different patterns of genomic alterations, with more frequent oncogenic amplification and less frequent inactivation of tumor suppressors, including CDKN2A. These data suggest that many EACs emerge not through the gradual accumulation of tumor-suppressor alterations but rather through a more direct path whereby a TP53-mutant cell undergoes genome doubling, followed by the acquisition of oncogenic amplifications.

DOI10.1038/ng.3343
Alternate JournalNat Genet
PubMed ID26192918
PubMed Central IDPMC4552571
Grant ListL30 CA179766 / CA / NCI NIH HHS / United States
U54 HG003067 / HG / NHGRI NIH HHS / United States
T32 HL007627 / HL / NHLBI NIH HHS / United States
U54 CA163059 / CA / NCI NIH HHS / United States
K08 CA134931 / CA / NCI NIH HHS / United States
K07 CA151613 / CA / NCI NIH HHS / United States
T32 CA009676 / CA / NCI NIH HHS / United States
P50CA127003 / CA / NCI NIH HHS / United States
P01 CA098101 / CA / NCI NIH HHS / United States
U54 HG0003067 / HG / NHGRI NIH HHS / United States
P50 CA127003 / CA / NCI NIH HHS / United States
T32 GM007748 / GM / NIGMS NIH HHS / United States
U54 CA163004 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700